Dyne Therapeutics/$DYN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Dyne Therapeutics
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
- Ticker
- $DYN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 289
- Headquarters
- Waltham, United States
- Website
- www.dyne-tx.com
DYN Metrics
BasicAdvanced
$3.1B
-
-$3.35
1.08
-
Price and volume
Market cap
$3.1B
Beta
1.08
52-week high
$27.31
52-week low
$14.00
Average daily volume
2.9M
Financial strength
Current ratio
12.02
Quick ratio
11.515
Long term debt to equity
0.305
Total debt to equity
0.332
Interest coverage (TTM)
-36.05%
Profitability
EBITDA (TTM)
-534.805
Management effectiveness
Return on assets (TTM)
-38.96%
Return on equity (TTM)
-81.57%
Valuation
Price to book
3.94
Price to tangible book (TTM)
3.94
Price to free cash flow (TTM)
-5.186
Free cash flow yield (TTM)
-19.28%
Free cash flow per share (TTM)
-3.218
Growth
Earnings per share change (TTM)
-13.46%
3-year earnings per share growth (CAGR)
-0.79%
What the Analysts think about DYN
Analyst ratings (Buy, Hold, Sell) for Dyne Therapeutics stock.
Analyst projections of the future price of Dyne Therapeutics stock.
Bulls say / Bears say
Dyne’s DMD drug z-rostudirsen has cleared an important regulatory hurdle: the FDA accepted its application for Priority Review and set a decision date of 21 January 2027. If approved, Dyne expects a potential US launch in the first quarter of 2027. (GlobeNewswire)
One-year Phase 1/2 data for z-basivarsen showed sustained improvements across several DM1 functional measures. At six months, hand-opening time improved by 3.2 seconds from baseline, compared with a 0.4-second worsening in the small placebo group. (GlobeNewswire)
Dyne reported $898.5 million in cash and investments at the end of June and raised about $405 million net through a July share offering. It expects these funds to support operations into the second quarter of 2028, giving it capital to advance trials and prepare for a potential launch. (GlobeNewswire)
A Phase 3 failure by Novartis in DM1 has made investors less confident that drugs targeting the disease can translate into functional benefit. J.P. Morgan downgraded Dyne, saying the setback made it harder to have conviction in z-basivarsen ahead of its own key data. (Seeking Alpha, Oninvest)
Z-rostudirsen’s application is based on a Phase 1/2 trial, while its confirmatory Phase 3 study has only just begun. The FDA decision therefore still carries clinical and regulatory risk, and full approval depends on further evidence. (GlobeNewswire, GlobeNewswire)
Operating costs are rising quickly: second-quarter research and development spending increased to $152.2 million from $99.2 million a year earlier. Dyne also raised about $405 million by issuing 21 million shares in July, extending its runway but diluting existing shareholders. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
DYN Financial Performance
Revenues and expenses
DYN Earnings Performance
Company profitability
Upcoming events
No upcoming events
DYN News
AllArticlesVideos
Funds containing DYN
Fund name | Fund size | $DYN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.20% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.20% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.08% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.